Biogen Deal History & Licensing Activity
Biogen is a large biotech headquartered in US. Over the past three years, Biogen has been involved in 8 licensing and acquisition transactions, with a primary focus on Antibodies (3 deals). The company currently has 50 active clinical trials, primarily in Rare Disease.
Deals (12mo)
5
Active Trials
50
Top Modality
Antibodies
Focus Area
Rare Disease
Biogen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Biogen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Felzartamab | TJ Bio | Antibodies | Phase 3 | license | Apr 20, 2026 |
| Syfovre + Empaveli (full company acquisition) | Apellis Pharmaceuticals | Mab | Approved | acquisition | Mar 31, 2026 |
| ALT-B4 | Biogen Inc. | Other | Unknown | license | Mar 25, 2026 |
| Undisclosed | Dayra Therapeutics | Peptides | Discovery | collaboration | Nov 24, 2025 |
| oral C5aR1 antagonist | Vanqua Bio | Small Molecules | Preclinical | license | Oct 24, 2025 |
Biogen Pipeline Focus
Therapeutic areas and modalities where Biogen is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Biogen Strategic Signals
Key indicators of Biogen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Biogen Clinical Pipeline
Biogen has 50 active clinical trials across 8 development phases.
17
Unknown
2
Not Applicable
1
Phase 4
7
Phase 1
1
Phase 1/2
8
Phase 2
1
Phase 2/3
13
Phase 3
See How Your Asset Matches Biogen's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Biogen Licensing & Deal Activity
Biogen is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Biogen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Biogen include Rare Disease (16 deals and trials), CNS Disorders (12 deals and trials), Immunology (8 deals and trials), and Autoimmune (6 deals and trials). In terms of modality, Biogen has shown particular interest in antibodies, other, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Biogen and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Biogen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.